top of page

Publications

Original Article

Intraperitoneal immunotherapy with denileukin diftitox (ONTAK) in recurrent refractory ovarian cancer

Clinical Trials

2024

Authors:

John B Liao, Nikita S Jejurikar, Katie M Hitchcock-Bernhardt, William R Gwin, Jessica L Reichow, Yushe Dang, Jennifer S Childs, Andrew L Coveler, Ron E Swensen, Barbara A Goff, Mary L Disis, Lupe G Salazar

Journal:

Gynecologic Oncology

Volume:

191

Page:

74-79

Original Articles

Magnitude of antigen-specific T-cell immunity the month after completing vaccination series predicts the development of long-term persistence of antitumor immune response

Cancer Vaccines

2024

Authors:

John B Liao, James Y Dai, Jessica L Reichow, Jong-Baeck Lim, Katie M Hitchcock-Bernhardt, Sasha E Stanton, Lupe G Salazar, Theodore A Gooley, Mary L Disis

Journal:

Journal for Immunotherapy of Cancer

Volume:

12(11)

Page:

e010251

Original Article

A Phase I/II Trial of HER2 Vaccine-Primed Autologous T-Cell Infusions in Patients with Treatment Refractory HER2-Overexpressing Breast Cancer

Clinical Trials

2023

Authors:

Disis ML, Dang Y, Coveler AL, Childs JS, Higgins DM, Liu Y, Zhou J, Mackay S, Salazar LG

Journal:

Clinical Cancer Research

Volume:

29(17)

Page:

3362-3371

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer

2023

Authors:

Disis, ML, Adams, SF, Bajpai, J, Butler, MO, Curiel, T, Dodt, SA, Doherty, L, Emens, LA, Friedman, CF, Gatti-Mays, M, Geller, MA, Jazaeri, A, John, VS, Kurnit, KC, Liao, JB, Mahdi, H, Mills, A, Zsiros, E, and Odunsi, K

Journal:

Journal for Immunotherapy of Cancer

Volume:

11

Page:

Original Article

Anti-tumor activity of a T-helper 1 multiantigen vaccine in a murine model of prostate cancer

Cancer Vaccines

2022

Authors:

Cecil, D.L., Curtis, B, Gad, E., Gormley, M, Timms, A.E., Corulli, L., Bos, R., Damle, R.N., Sepulveda, M.A., and Disis, M.L.

Journal:

Scientific Reports

Volume:

12

Page:

13618

Original Article

COX-2 Inhibitors Decrease Expression of PD-L1 in Colon Tumors and Increase the Influx of Type I Tumor-infiltrating Lymphocytes

Cancer Vaccines

2022

Authors:

Cecil DL, Gad EA, Corulli LR, Drovetto N, Lubet RA, Disis ML

Journal:

Cancer Prevention Research

Volume:

15(4)

Page:

225-231

Original Article

Unexpected Liver and Kidney Pathology in C57BL/6J Mice Fed a High-fat Diet and Given Azoxymethane to Induce Colon Cancer

Cancer Vaccines

2022

Authors:

Waggie, KS, Corulli, LR, Cecil, D, Rodmaker, ER, Walsh, C, and Disis, ML

Journal:

Comparative Medicine

Volume:

72(5)

Page:

330-335

Original Article

Safety and Outcomes of a Plasmid DNA Vaccine Encoding the ERBB2 Intracellular Domain in Patients With Advanced-Stage ERBB2-Positive Breast Cancer

Clinical Trials

2022

Authors:

Disis, ML, Guthrie, KA, Liu, Y, Coveler, AL, Higgins, DM, Childs, JS, Dang, Y, and Salazar, LG

Journal:

JAMA Oncology

Volume:

9(1)

Page:

71-78

Review Article

Therapeutic cancer vaccines revamping: technology advancements and pitfalls

Cancer Vaccines

2021

Authors:

Antonarelli G, Corti C, Tarantino P, Ascione L, Cortes J, Romero P, Mittendorf EA, Disis ML, Curigliano G

Journal:

Annals of Oncology

Volume:

32(12)

Page:

1537-1551

Original Article

Tumor-associated autoantibodies from mouse breast cancer models are found in serum of breast cancer patients

2021

Authors:

Stanton, SE, Gad E, Ramos, E, Corulli LR, Annis, J, Katayama, H, Hamash S and Disis, ML

Journal:

Nature Partner Journals Breast Cancer

Volume:

7(1)

Page:

50

bottom of page